Premier Biomedical, Inc. (BIEI) Stock

About Premier Biomedical, Inc.

Premier Biomedical, Inc., a research-based company, discovers and develops medical products for the treatment of PTSD, cancer, and various other diseases. It offers pain management products comprising pain relief patch of hemp oil extracts; water-based and oil-based roll-on applicators; oil-based pump spray applicators; and ointments through its Website painreliefmeds.com and various distributors. It is also developing hemp oil products, including anti-pain patch, roll-on topical products, sprays, ointments, tincture drop product, a hemp oil capsule, and pet product; sequential-dialysis technique for cancer, Alzheimer’s disease, ALS, blood sepsis, leukemia, and other life-threatening cancers; and Feldetrex drug candidate for the treatment of multiple sclerosis, fibromyalgia, neuropathic pain, and traumatic brain injuries. Premier Biomedical, Inc. was founded in 2010 and is headquartered in Jackson Center, Pennsylvania.

Premier Biomedical, Inc. (BIEI) stock trades at $0.00 with a market capitalization of $1.04M. The stock is valued at a price-to-earnings (P/E) ratio of -12.66, price-to-book of -0.43, price-to-sales of 78.42. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Premier Biomedical, Inc. generates a return on equity (ROE) of 0.00%, return on capital employed of 3.43%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.premierbiomedical.com